Newer
Older
Digital_Repository / Misc / Mass downloads / UTas / 1773.html
  1. <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  2. "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
  3. <html>
  4. <head>
  5. <title>UTas ePrints - Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group</title>
  6. <script type="text/javascript" src="http://eprints.utas.edu.au/javascript/auto.js"><!-- padder --></script>
  7. <style type="text/css" media="screen">@import url(http://eprints.utas.edu.au/style/auto.css);</style>
  8. <style type="text/css" media="print">@import url(http://eprints.utas.edu.au/style/print.css);</style>
  9. <link rel="icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  10. <link rel="shortcut icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  11. <link rel="Top" href="http://eprints.utas.edu.au/" />
  12. <link rel="Search" href="http://eprints.utas.edu.au/cgi/search" />
  13. <meta content="Adams, M.J." name="eprints.creators_name" />
  14. <meta content="Ward, C." name="eprints.creators_name" />
  15. <meta content="Thom, J." name="eprints.creators_name" />
  16. <meta content="Bianchi, A." name="eprints.creators_name" />
  17. <meta content="Perrin, E." name="eprints.creators_name" />
  18. <meta content="Coghlan, D." name="eprints.creators_name" />
  19. <meta content="Smith, M." name="eprints.creators_name" />
  20. <meta content="Murray.Adams@utas.edu.au" name="eprints.creators_id" />
  21. <meta content="" name="eprints.creators_id" />
  22. <meta content="" name="eprints.creators_id" />
  23. <meta content="" name="eprints.creators_id" />
  24. <meta content="" name="eprints.creators_id" />
  25. <meta content="" name="eprints.creators_id" />
  26. <meta content="" name="eprints.creators_id" />
  27. <meta content="article" name="eprints.type" />
  28. <meta content="2007-09-12" name="eprints.datestamp" />
  29. <meta content="2008-01-08 15:30:00" name="eprints.lastmod" />
  30. <meta content="show" name="eprints.metadata_visibility" />
  31. <meta content="Emerging technologies in hemostasis
  32. diagnostics: A report from the Australasian
  33. Society of Thrombosis and Haemostasis
  34. Emerging Technologies Group" name="eprints.title" />
  35. <meta content="pub" name="eprints.ispublished" />
  36. <meta content="321008" name="eprints.subjects" />
  37. <meta content="restricted" name="eprints.full_text_status" />
  38. <meta content="Hemostasis, laboratory testing, thrombin generation, thrombophilia, bleeding" name="eprints.keywords" />
  39. <meta content="Copyright 2007, Georg Thieme Verlag. Definitive version is available online at http://www.thieme-connect.de/ejournals/toc/sth/6268" name="eprints.note" />
  40. <meta content="Technology in hemostasis laboratories has evolved enormously during the last
  41. 30 years. Although many scientists and clinicians will remember the traditional tilt-tube
  42. techniques to screen for coagulation abnormalities and to monitor anticoagulant therapy,
  43. the hemostasis laboratory today uses a variety of modern technologies. These include flow
  44. cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), immunologic
  45. assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific
  46. coagulation proteins, and platelet function analyzers. Although these advances in technology
  47. have resulted in greater capability, productivity, sensitivity, specificity, and ultimately,
  48. improvement in the clinical care of patients, controversies and limitations remain.
  49. This article highlights new and emerging technologies in hemostasis and discusses whether
  50. they have improved or are likely to improve laboratory diagnostics by specifically addressing
  51. the following: (1) Can new technologies help predict likelihood of thrombosis recurrence?
  52. (2) Has an understanding of the role of a disintegrin-like and metalloprotease with
  53. thrombospondin type 1 motifs (ADAMTS13) in microangiopathy resulted in improved
  54. diagnostic methods for this disorder? (3) Does thrombelastography allow better definition
  55. of bleeding risk than conventional hemostasis assays, especially in settings of acute
  56. hemostatic pathology?" name="eprints.abstract" />
  57. <meta content="2007-04" name="eprints.date" />
  58. <meta content="published" name="eprints.date_type" />
  59. <meta content="Seminars in Thrombosis and Hemostasis" name="eprints.publication" />
  60. <meta content="33" name="eprints.volume" />
  61. <meta content="3" name="eprints.number" />
  62. <meta content="226-234" name="eprints.pagerange" />
  63. <meta content="10.1055/s-2007-971808" name="eprints.id_number" />
  64. <meta content="UNSPECIFIED" name="eprints.thesis_type" />
  65. <meta content="TRUE" name="eprints.refereed" />
  66. <meta content="0094-6176" name="eprints.issn" />
  67. <meta content="http://dx.doi.org/10.1055/s-2007-971808" name="eprints.official_url" />
  68. <meta content="1. Prandoni P, Lensing AW, Cogo A, et al. The long-term
  69. clinical course of acute deep venous thrombosis. Ann Intern
  70. Med 1996;125:1–7
  71. 2. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin
  72. antibodies predict early recurrence of thromboembolism and
  73. death among patients with venous thromboembolism following
  74. anticoagulant therapy. Duration of Anticoagulation
  75. Study Group. Am J Med 1998;104:332–338
  76. 3. Kearon C, Gent M, Hirsh J, et al. A comparison of three
  77. months of anticoagulation with extended anticoagulation for
  78. a first episode of idiopathic venous thromboembolism.
  79. N Engl J Med 1999;340:901–907
  80. 4. Kraaijenhagen RA, Haverkamp D, Koopman MM, et al.
  81. High plasma concentration of factor VIIIc is a major risk
  82. factor for venous thromboembolism. Thromb Haemost 2000;
  83. 83:5–9
  84. 5. Kyrle PA, Minar E, Hisrchl M, et al. High plasma levels of
  85. factor VIII and the risk of recurrent venous thromboembolism.
  86. N Engl J Med 2000;343:457–462
  87. EMERGING TECHNOLOGIES IN HEMOSTASIS DIAGNOSTICS/ADAMS ET AL 2316. Kyrle PA, Eichinger S. The risk of recurrent venous
  88. thromboembolism: the Austrian Study on Recurrent Venous
  89. Thromboembolism (review). Wien Klin Wochenschr 2003;
  90. 115:471–474
  91. 7. Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic
  92. abnormalities and recurrence of venous thromboembolism
  93. in patients treated with standardized anticoagulant
  94. treatment. Thromb Res 2005;116:301–306
  95. 8. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate
  96. after a first venous thrombosis in patients with familial
  97. thrombophilia. Arterioscler Thromb Vasc Biol 2005;25:
  98. 1992–1997
  99. 9. Ke´vorkian J-P, Halimi C, Segrestaa J-M, et al. Monitoring
  100. of patients with deep-vein thrombosis during and after
  101. anticoagulation with D-dimer. Lancet 1998;351:571–
  102. 572
  103. 10. Fattorini A, Crippa L, D’Angelo SV, et al. Risk of deep vein
  104. thrombosis recurrence: high negative predictive value of
  105. D-dimer performed during oral anticoagulation. Thromb
  106. Haemost 2002;88:162–163
  107. 11. Palareti G, Legnani C, Cosmi B, et al. Risk of venous
  108. thromboembolism recurrence: high negative predictive value
  109. of D-dimer performed after oral anticoagulation is stopped.
  110. Thromb Haemost 2002;87:7–12
  111. 12. Palareti G, Legnani C, Cosmi B, et al. Predictive value of
  112. D-dimer test for recurrent venous thromboembolism after
  113. anticoagulation withdrawal in subjects with a previous
  114. idiopathic event and in carriers of congenital thrombophilia.
  115. Circulation 2003;108:313–318
  116. 13. Cosmi B, Legnani C, Cini M, et al. D-dimer levels in
  117. combination with residual venous obstruction and the risk of
  118. recurrence after anticoagulation withdrawal for a first
  119. idiopathic deep vein thrombosis. Thromb Haemost 2005;
  120. 94:969–974
  121. 14. Baglin T. The measurement and application of thrombin
  122. generation. Br J Haematol 2005;130:653–661
  123. 15. Wielders S, Mukherjee M, Michiels J, et al. The routine
  124. determination of the endogenous thrombin potential, first
  125. results in different forms of hyper- and hypocoagulability.
  126. Thromb Haemost 1997;77:629–636
  127. 16. Hemker HC, Giesen P, Al Dieri R, et al. The calibrated
  128. automated thrombogram (CAT): a universal routine test for
  129. hyper- and hypocoagulability. Pathophysiol Haemost Thromb
  130. 2002;32:249–253
  131. 17. Hemker HC, Giesen PLA, Al Dieri R, et al. Calibrated
  132. automated thrombin generation measurement in clotting
  133. plasma. Pathophysiol Haemost Thromb 2003;33:4–15
  134. 18. Gerotziafas GT, Despasse F, Busson J, et al. Towards a
  135. standardization of thrombin generation assessment: the
  136. influence of tissue factor, platelets and phospholipids
  137. concentration on the normal values of Thrombogram-
  138. Thrombinoscope assay. Thromb J 2005;3:16
  139. 19. Andresen MS, Abilgaard U, Liestol S, et al. The ability of
  140. three global plasma assays to recognize thrombophilia.
  141. Thromb Res 2004;113:411–417
  142. 20. Regnault V, Hemker HC, Wahlo D, et al. Phenotyping the
  143. haemostatic system by thrombography—potential for the
  144. estimation of thrombotic risk. Thromb Res 2004;114:539–
  145. 545
  146. 21. Eichinger S, Weltermann A, Phillip K, et al. Prospective
  147. evaluation of haemostatic system activation and thrombin
  148. potential in healthy pregnant women with and without factor
  149. V Leiden. Thromb Haemost 1999;82:1232–1236
  150. 22. Hron G, Kollars M, Binder BR, et al. Identification of
  151. patients at low risk for recurrent venous thromboembolism
  152. by measuring thrombin generation. JAMA 2006;296:397–
  153. 402
  154. 23. He S, Antovic A, Blo¨mback M. A simple and rapid
  155. laboratory method for determination of haemostasis potential
  156. in plasma—II. Modifications for use in routine laboratories
  157. and research work. Thromb Res 2001;103:355–361
  158. 24. Antovic A, Blomba¨ck M, Bremme K, et al. Increased
  159. hemostasis potential persists in women with previous
  160. thromboembolism with or without APC resistance.
  161. J Thromb Haemost 2003;1:2531–2535
  162. 25. Morel-Kopp M-C, Curnow J, Aboud M, et al. Discrepancies
  163. between the overall coagulation potential (OCP) assay and
  164. international normalised ratio (INR) in warfarin-treated
  165. patients. J Thromb Haemost 2005;3(suppl 1):1376
  166. 26. Exner T, Joseph J, Low J, et al. A new activated factor Xbased
  167. clotting method with improved specificity for procoagulant
  168. phospholipids. Blood Coagul Fibrinolysis 2003;14:
  169. 773–779
  170. 27. Favaloro EJ, Soltani S, McDonald J, et al. Laboratory
  171. identification of familial thrombophilia: do the pitfalls
  172. exceed the benefits? A reassessment of ABO-blood group,
  173. gender, age, and other laboratory parameters on the
  174. potential influence on a diagnosis of protein c, protein s,
  175. and antithrombin deficiency and the potential high risk of
  176. a false positive diagnosis. Lab Hematol 2005;11:174–
  177. 184
  178. 28. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic
  179. purpura with plasma. N Engl J Med 1977;297:
  180. 1386–1389
  181. 29. George JN. How I treat patients with thrombotic thrombocytopenic
  182. purpura-hemolytic uremic syndrome. Blood 2000;
  183. 96:1223–1229
  184. 30. Furlan M, Robles R, La¨mmle B. Partial purification and
  185. characterization of a protease from human plasma cleaving
  186. von Willebrand factor to fragments produced by in vivo
  187. proteolysis. Blood 1996;87:4223–4234
  188. 31. Tsai HM. Physiological cleavage of von Willebrand factor by
  189. a plasma protease is dependent on its conformation and
  190. requires calcium ion. Blood 1996;87:4235–4244
  191. 32. Furlan M, Robles R, Solenthaler M, et al. Deficient activity
  192. of von Willebrand factor cleavage-cleaving protease in a
  193. patient with thrombotic thrombocytopenic purpura. Blood
  194. 1997;89:3097–3103
  195. 33. Furlan M, Robles R, Solenthaler M, et al. Acquired
  196. deficiency of von Willebrand factor cleavage-cleaving protease
  197. in a patient with thrombotic thrombocytopenic purpura.
  198. Blood 1998;91:2839–2846
  199. 34. Zheng X, Chung D, Tkayama TK, et al. Structure of von
  200. Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease
  201. involved in thrombotic thrombocytopenic purpura.
  202. J Biol Chem 2001;276:41059–41063
  203. 35. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma
  204. FVIII:von Willebrand factor multimers in chronic relapsing
  205. thrombotic thrombocytopenic purpura. N Engl J Med 1982;
  206. 307:1432–1435
  207. 36. La¨mmle B, Kremer Hovinga JA, Alberio L. Thrombotic
  208. thrombocytopenic purpura. J Thromb Haemost 2005;3:
  209. 1663–1675
  210. 37. Moake JL. Von Willebrand factor, ADAMTS-13 and
  211. thrombotic thrombocytopenic purpura. Semin Hematol
  212. 2004;41:4–14
  213. 232 SEMINARS IN THROMBOSIS AND HEMOSTASIS/VOLUME 33, NUMBER 3 2007
  214. 38. Meyer D, Obert B, Pietu G, et al. Multimeric structure of
  215. factor VIII/von Willebrand factor in von Willebrand’s
  216. disease. J Lab Clin Med 1980;95:590–602
  217. 39. Baillod P, Affolter B, Kurt GH, et al. Multimeric analysis of
  218. von Willebrand factor by vertical sodium dodecyl sulphate
  219. agarose gel electrophoresis, vacuum blotting technology and
  220. sensitive visualisation by alkaline phosphatase complex.
  221. Thromb Res 1992;66:745–755
  222. 40. Veyradier A, Girma J-P. Assays of ADAMTS-13 activity.
  223. Semin Hematol 2004;41:41–47
  224. 41. Allford SL, Harrison P, Lawrie AS, et al. von Willebrand
  225. factor-cleaving protease activity in congenital thrombotic
  226. thrombocytopenic purpura. Br J Haematol 2000;111:1215–
  227. 1222
  228. 42. Van der Plas RM, Schiphorst ME, Huizinga EG, et al. von
  229. Willebrand factor proteolysis is deficient in classic, but not in
  230. bone marrow transplantation-associated, thrombotic thrombocytopenic
  231. purpura. Blood 1999;93:3798–3802
  232. 43. Krizek DM, Rick ME. A rapid method to visualize von
  233. Willebrand factor multimers by using agarose electrophoresis,
  234. immunolocalization and luminographic detection. Thromb
  235. Res 2000;97:457–462
  236. 44. Obert B, Tout H, Veyradier A, et al. Estimation of the von
  237. Willebrand factor-cleaving protease in plasma using monoclonal
  238. antibodies to vWF. Thromb Haemost 1999;82:1382–
  239. 1385
  240. 45. Veyradier A, Obert B, Houllier A, et al. Specific von
  241. Willebrand factor-cleaving protease in thrombotic microangiopathies.
  242. Blood 2001;98:1765–1772
  243. 46. Gerritsen HE, Turecek PL, Schwartz HP, et al. Assay of von
  244. Willebrand factor (vWF)-cleaving protease based on
  245. decreased collagen binding affinity of degraded vWF: a tool
  246. for the diagnosis of thrombotic thrombocytopenic purpura
  247. (TTP). Thromb Haemost 1999;82:1386–1389
  248. 47. Aronson DL, Krizek DM, Rick ME. A rapid assay for the
  249. vWF protease. Thromb Haemost 2001;85:184–185
  250. 48. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand
  251. cleaving protease and ADAMTS-13 mutations in childhood
  252. TTP. Blood 2003;101:1845–1850
  253. 49. Bo¨hm M, Vigh T, Scharrer I. Evaluation and clinical
  254. application of a new method for measuring activity of von
  255. Willebrand factor-cleaving metalloprotease (ADAMTS-13).
  256. Ann Hematol 2002;81:430–435
  257. 50. Kostousov V, Fehr J, Bombeli T. Novel, semi-automated, 60-
  258. min-assay to determine von Willebrand factor cleaving
  259. activity of ADAMTS-13. Thromb Res 2006;118:723–731
  260. 51. Shenkman B, Budde U, Angerhaus D, et al. D. ADAMTS-
  261. 13 regulates platelet adhesion under flow. Thromb Haemost
  262. 2006;96:160–166
  263. 52. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a
  264. first fluorogenic substrate for ADAMTS-13 assay. Br J
  265. Haematol 2005;129:93–100
  266. 53. Yagi H, Matsumoto M, Iwamoto T, et al. Heightened
  267. proteolysis of plasma ADAMTS-13 antigen in patients with
  268. thrombotic thrombocytopenic purpura. Blood 2004;104:
  269. 3946(Abst)
  270. 54. Wu J-J, Fujikawa K, Lian EC, et al. A rapid enzyme linked
  271. assay for ADAMTS-13. J Thromb Haemost 2006;4:129–136
  272. 55. Rieger M, Ferrari S, Kremer Hovinga JA, et al. Relation
  273. between ADAMTS-13 activity and ADAMTS-13 antigen
  274. levels in healthy donors and patients with thrombotic
  275. microangiopathies (TMA). Thromb Haemost 2006;95:212–
  276. 220
  277. 56. Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level
  278. determination uncovers antigen absence in acquired thrombotic
  279. thrombocytopenic purpura and ethnic differences.
  280. J Thromb Haemost 2006;4:955–962
  281. 57. Park YD, Yoshioka A, Kawa K, et al. Impaired activity of von
  282. Willebrand factor-cleaving protease may predict the occurrence
  283. of hepatic veno-occlusive disease after stem cell
  284. transplantation. Bone Marrow Transplant 2002;29:789–794
  285. 58. Scheiflinger F, Kno¨bl P, Trattner B, et al. Nonneutralizing
  286. IgM and IgG antibodies to von Willebrand factor cleaving
  287. protease in a patient with thrombotic thrombocytopenic
  288. purpura. Blood 2003;102:3241–3243
  289. 59. Kremer Hovinga JA, Studt JD, Alberio L, et al. von
  290. Willebrand factor-cleaving protease (ADAMTS13) activity
  291. determination in the diagnosis of thrombotic microangiopathies:
  292. the Swiss experience. Semin Hematol 2004;41:75–
  293. 82
  294. 60. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic
  295. thrombocytopenic purpura? J Thromb Haemost 2003;
  296. 1:632–634
  297. 61. Tsai HM. Is severe deficiency of ADAMTS-13 specific for
  298. thrombotic thrombocytopenic purpura? Yes. J Thromb
  299. Haemost 2003;1:625–631
  300. 62. Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity
  301. of von Willebrand factor-cleaving protease is not restricted to
  302. patients suffering from thrombotic thrombocytopenic purpura.
  303. Br J Haematol 2001;112:1087–1088
  304. 63. Moore JC, Hayward CP, Warkentin TE, et al. Decreased
  305. von Willebrand factor protease activity associated with
  306. thrombocytopenic disorders. Blood 2001;98:1842–1846
  307. 64. Koh MB, Hunt BJ. The management of peri-operative
  308. bleeding. Blood Rev 2003;17:179–185
  309. 65. Levy JH. Massive transfusion coagulopathy. Semin Hematol
  310. 2006;43(1, suppl 1):S59–S63
  311. 66. Rivard GE, Brummel-Ziedins KE, Mann KG, et al.
  312. Evaluation of the profile of thrombin generation during the
  313. process of whole blood clotting as assessed by thromboelastography.
  314. J Thromb Haemost 2005;3:2039–2043
  315. 67. Kolde HJ, Strobel GA. Whole blood global haemostasis assay
  316. via collagen mediated activation of the haemostasis system.
  317. Ann Hematol 2003;82(suppl 1):S147
  318. 68. Mallett SV, Cox DJA. Thromboelastography. Br J Anaesth
  319. 1992;69:307–313
  320. 69. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of
  321. structured use of routine laboratory tests or near patient
  322. assessment with clinical judgment in the management of
  323. bleeding after cardiac surgery. Br J Anaesth 2004;92:178–186
  324. 70. Luddington RJ. Thrombelastography/thromboelastometry.
  325. Clin Lab Haematol 2005;27:81–90
  326. 71. Piraccini E, Zanzani C, Caporossi E. Intraoperative
  327. coagulation monitoring and small bowel transplantation: a
  328. way to explore. Transplant Proc 2006;38:823–825
  329. 72. Gillies BS. Thromboelastography and liver transplantation.
  330. Semin Thromb Hemost 1995;21(suppl 4):45–49
  331. 73. Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of
  332. thromboelastography in assessment of trauma patient coagulation.
  333. J Trauma 1997;42:716–720
  334. 74. Vorweg M, Hipp RFJ, Schindler A, et al. Management of
  335. coagulation in trauma patients using a new monitoring
  336. method. Anesth Analg 1996;82:S54
  337. 75. Fries D, Innerhofer P, Schobersberger W. Coagulation
  338. management in trauma patients. Curr Opin Anaesthesiol
  339. 2002;15:217–223
  340. EMERGING TECHNOLOGIES IN HEMOSTASIS DIAGNOSTICS/ADAMS ET AL 233
  341. 76. Savry C, Quinio P, Lefevre F, et al. Manageability and
  342. potential for haemostasis monitoring by near-patient modi-
  343. fied thromboelastometer (Rotem) in intensive care unit. Ann
  344. Fr Anesth Reanim 2005;24:607–616
  345. 77. Pusateri AE, Park MS. Mechanist implications for the use
  346. and monitoring of recombinant activated factor VII in
  347. trauma. Crit Care 2005;9(Suppl 5):S15–S24
  348. 78. Ingerslev J, Christiansen K, Calatzis A, et al. Management
  349. and monitoring of recombinant factor VII. Blood Coagul
  350. Fibrinolysis 2000;11(suppl 1):S25–S30
  351. 79. Kawaguchi C, Takahashi Y, Hanesaka Y, et al. The in vitro
  352. analysis of the coagulation mechanism of activated factor VII
  353. using thromboelastogram.ThrombHaemost 2002;88:768–772
  354. 80. Shore-Lesserson L, Manspeizer H, DePerio M, et al.
  355. Thromboelastography-guided transfusion algorithm reduces
  356. transfusion in complex cardiac surgery. Anesth Analg 1999;
  357. 88:312–319
  358. 81. Royston D, von Kier S. Reduced haemostatic factor
  359. transfusion using heparinase-modified thromboelastography
  360. during cardio-pulmonary by-pass. Br J Anaesth 2001;86:
  361. 575–578
  362. 82. Anderson L, Quasim I, Steven M, et al. An audit of red cell
  363. and blood product use after institution of thromboelastography
  364. in a cardiac intensive care unit. Br J Haematol 2003;
  365. 121(suppl 1):80
  366. 83. Williams GD, Bratton SL, Riley EC, et al. Coagulation tests
  367. during cardiopulmonary bypass correlate with blood loss in
  368. children undergoing cardiac surgery. J Cardiothorac Vasc
  369. Anesth 1999;13:398–404
  370. 84. Cammerer U, Dietrich W, Rampf T, et al. The predictive
  371. value of modified computerized thromboelastography
  372. and platelet function analysis for postoperative blood loss
  373. in routine cardiac surgery. Anesth Analg 2003;96:51–
  374. 57
  375. 85. Wettstein P, Haeberli A, Stutz M, et al. Decreased factor
  376. XIII availability for thrombin and early loss of clot firmness
  377. in patients with unexplained intraoperative bleeding. Anesth
  378. Analg 2004;99:1564–1569
  379. 234 SEMINARS IN THROMBOSIS AND HEMOSTASIS/VOLUME 33, NUMBER 3 2007" name="eprints.referencetext" />
  380. <meta content="Adams, M.J. and Ward, C. and Thom, J. and Bianchi, A. and Perrin, E. and Coghlan, D. and Smith, M. (2007) Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Seminars in Thrombosis and Hemostasis, 33 (3). pp. 226-234. ISSN 0094-6176" name="eprints.citation" />
  381. <meta content="http://eprints.utas.edu.au/1773/1/Adams_etal_2007_(ASTH).pdf" name="eprints.document_url" />
  382. <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
  383. <meta content="Emerging technologies in hemostasis
  384. diagnostics: A report from the Australasian
  385. Society of Thrombosis and Haemostasis
  386. Emerging Technologies Group" name="DC.title" />
  387. <meta content="Adams, M.J." name="DC.creator" />
  388. <meta content="Ward, C." name="DC.creator" />
  389. <meta content="Thom, J." name="DC.creator" />
  390. <meta content="Bianchi, A." name="DC.creator" />
  391. <meta content="Perrin, E." name="DC.creator" />
  392. <meta content="Coghlan, D." name="DC.creator" />
  393. <meta content="Smith, M." name="DC.creator" />
  394. <meta content="321008 Haematology" name="DC.subject" />
  395. <meta content="Technology in hemostasis laboratories has evolved enormously during the last
  396. 30 years. Although many scientists and clinicians will remember the traditional tilt-tube
  397. techniques to screen for coagulation abnormalities and to monitor anticoagulant therapy,
  398. the hemostasis laboratory today uses a variety of modern technologies. These include flow
  399. cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), immunologic
  400. assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific
  401. coagulation proteins, and platelet function analyzers. Although these advances in technology
  402. have resulted in greater capability, productivity, sensitivity, specificity, and ultimately,
  403. improvement in the clinical care of patients, controversies and limitations remain.
  404. This article highlights new and emerging technologies in hemostasis and discusses whether
  405. they have improved or are likely to improve laboratory diagnostics by specifically addressing
  406. the following: (1) Can new technologies help predict likelihood of thrombosis recurrence?
  407. (2) Has an understanding of the role of a disintegrin-like and metalloprotease with
  408. thrombospondin type 1 motifs (ADAMTS13) in microangiopathy resulted in improved
  409. diagnostic methods for this disorder? (3) Does thrombelastography allow better definition
  410. of bleeding risk than conventional hemostasis assays, especially in settings of acute
  411. hemostatic pathology?" name="DC.description" />
  412. <meta content="2007-04" name="DC.date" />
  413. <meta content="Article" name="DC.type" />
  414. <meta content="PeerReviewed" name="DC.type" />
  415. <meta content="application/pdf" name="DC.format" />
  416. <meta content="http://eprints.utas.edu.au/1773/1/Adams_etal_2007_(ASTH).pdf" name="DC.identifier" />
  417. <meta content="http://dx.doi.org/10.1055/s-2007-971808" name="DC.relation" />
  418. <meta content="Adams, M.J. and Ward, C. and Thom, J. and Bianchi, A. and Perrin, E. and Coghlan, D. and Smith, M. (2007) Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Seminars in Thrombosis and Hemostasis, 33 (3). pp. 226-234. ISSN 0094-6176" name="DC.identifier" />
  419. <meta content="http://eprints.utas.edu.au/1773/" name="DC.relation" />
  420. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/BibTeX/epprod-eprint-1773.bib" title="BibTeX" type="text/plain" />
  421. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/ContextObject/epprod-eprint-1773.xml" title="OpenURL ContextObject" type="text/xml" />
  422. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/ContextObject::Dissertation/epprod-eprint-1773.xml" title="OpenURL Dissertation" type="text/xml" />
  423. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/ContextObject::Journal/epprod-eprint-1773.xml" title="OpenURL Journal" type="text/xml" />
  424. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/DC/epprod-eprint-1773.txt" title="Dublin Core" type="text/plain" />
  425. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/DIDL/epprod-eprint-1773.xml" title="DIDL" type="text/xml" />
  426. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/EndNote/epprod-eprint-1773.enw" title="EndNote" type="text/plain" />
  427. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/HTML/epprod-eprint-1773.html" title="HTML Citation" type="text/html; charset=utf-8" />
  428. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/METS/epprod-eprint-1773.xml" title="METS" type="text/xml" />
  429. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/MODS/epprod-eprint-1773.xml" title="MODS" type="text/xml" />
  430. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/RIS/epprod-eprint-1773.ris" title="Reference Manager" type="text/plain" />
  431. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/Refer/epprod-eprint-1773.refer" title="Refer" type="text/plain" />
  432. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/Simple/epprod-eprint-1773text" title="Simple Metadata" type="text/plain" />
  433. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/Text/epprod-eprint-1773.txt" title="ASCII Citation" type="text/plain; charset=utf-8" />
  434. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/1773/XML/epprod-eprint-1773.xml" title="EP3 XML" type="text/xml" />
  435.  
  436. </head>
  437. <body bgcolor="#ffffff" text="#000000" onLoad="loadRoutine(); MM_preloadImages('images/eprints/ePrints_banner_r5_c5_f2.gif','images/eprints/ePrints_banner_r5_c7_f2.gif','images/eprints/ePrints_banner_r5_c8_f2.gif','images/eprints/ePrints_banner_r5_c9_f2.gif','images/eprints/ePrints_banner_r5_c10_f2.gif','images/eprints/ePrints_banner_r5_c11_f2.gif','images/eprints/ePrints_banner_r6_c4_f2.gif')">
  438. <div class="ep_noprint"><noscript><style type="text/css">@import url(http://eprints.utas.edu.au/style/nojs.css);</style></noscript></div>
  439.  
  440.  
  441.  
  442.  
  443. <table width="795" border="0" cellspacing="0" cellpadding="0">
  444. <tr>
  445. <td><script language="JavaScript1.2">mmLoadMenus();</script>
  446. <table border="0" cellpadding="0" cellspacing="0" width="795">
  447. <!-- fwtable fwsrc="eprints_banner_final2.png" fwbase="ePrints_banner.gif" fwstyle="Dreamweaver" fwdocid = "1249563342" fwnested="0" -->
  448. <tr>
  449. <td><img src="/images/eprints/spacer.gif" width="32" height="1" border="0" alt="" /></td>
  450. <td><img src="/images/eprints/spacer.gif" width="104" height="1" border="0" alt="" /></td>
  451. <td><img src="/images/eprints/spacer.gif" width="44" height="1" border="0" alt="" /></td>
  452. <td><img src="/images/eprints/spacer.gif" width="105" height="1" border="0" alt="" /></td>
  453. <td><img src="/images/eprints/spacer.gif" width="41" height="1" border="0" alt="" /></td>
  454. <td><img src="/images/eprints/spacer.gif" width="16" height="1" border="0" alt="" /></td>
  455. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  456. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  457. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  458. <td><img src="/images/eprints/spacer.gif" width="82" height="1" border="0" alt="" /></td>
  459. <td><img src="/images/eprints/spacer.gif" width="69" height="1" border="0" alt="" /></td>
  460. <td><img src="/images/eprints/spacer.gif" width="98" height="1" border="0" alt="" /></td>
  461. <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  462. </tr>
  463. <tr>
  464. <td colspan="12"><img name="ePrints_banner_r1_c1" src="/images/eprints/ePrints_banner_r1_c1.gif" width="795" height="10" border="0" alt="" /></td>
  465. <td><img src="/images/eprints/spacer.gif" width="1" height="10" border="0" alt="" /></td>
  466. </tr>
  467. <tr>
  468. <td rowspan="6"><img name="ePrints_banner_r2_c1" src="/images/eprints/ePrints_banner_r2_c1.gif" width="32" height="118" border="0" alt="" /></td>
  469. <td rowspan="5"><a href="http://www.utas.edu.au/"><img name="ePrints_banner_r2_c2" src="/images/eprints/ePrints_banner_r2_c2.gif" width="104" height="103" border="0" alt="" /></a></td>
  470. <td colspan="10"><img name="ePrints_banner_r2_c3" src="/images/eprints/ePrints_banner_r2_c3.gif" width="659" height="41" border="0" alt="" /></td>
  471. <td><img src="/images/eprints/spacer.gif" width="1" height="41" border="0" alt="" /></td>
  472. </tr>
  473. <tr>
  474. <td colspan="3"><a href="http://eprints.utas.edu.au/"><img name="ePrints_banner_r3_c3" src="/images/eprints/ePrints_banner_r3_c3.gif" width="190" height="31" border="0" alt="" /></a></td>
  475. <td rowspan="2" colspan="7"><img name="ePrints_banner_r3_c6" src="/images/eprints/ePrints_banner_r3_c6.gif" width="469" height="37" border="0" alt="" /></td>
  476. <td><img src="/images/eprints/spacer.gif" width="1" height="31" border="0" alt="" /></td>
  477. </tr>
  478. <tr>
  479. <td colspan="3"><img name="ePrints_banner_r4_c3" src="/images/eprints/ePrints_banner_r4_c3.gif" width="190" height="6" border="0" alt="" /></td>
  480. <td><img src="/images/eprints/spacer.gif" width="1" height="6" border="0" alt="" /></td>
  481. </tr>
  482. <tr>
  483. <td colspan="2"><img name="ePrints_banner_r5_c3" src="/images/eprints/ePrints_banner_r5_c3.gif" width="149" height="1" border="0" alt="" /></td>
  484. <td rowspan="2" colspan="2"><a href="/information.html" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821132634_0,0,25,null,'ePrints_banner_r5_c5');MM_swapImage('ePrints_banner_r5_c5','','/images/eprints/ePrints_banner_r5_c5_f2.gif',1);"><img name="ePrints_banner_r5_c5" src="/images/eprints/ePrints_banner_r5_c5.gif" width="57" height="25" border="0" alt="About" /></a></td>
  485. <td rowspan="2"><a href="/view/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133021_1,0,25,null,'ePrints_banner_r5_c7');MM_swapImage('ePrints_banner_r5_c7','','/images/eprints/ePrints_banner_r5_c7_f2.gif',1);"><img name="ePrints_banner_r5_c7" src="/images/eprints/ePrints_banner_r5_c7.gif" width="68" height="25" border="0" alt="Browse" /></a></td>
  486. <td rowspan="2"><a href="/perl/search/simple" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133201_2,0,25,null,'ePrints_banner_r5_c8');MM_swapImage('ePrints_banner_r5_c8','','/images/eprints/ePrints_banner_r5_c8_f2.gif',1);"><img name="ePrints_banner_r5_c8" src="/images/eprints/ePrints_banner_r5_c8.gif" width="68" height="25" border="0" alt="Search" /></a></td>
  487. <td rowspan="2"><a href="/perl/register" onMouseOut="MM_swapImgRestore();MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_1018171924_3,0,25,null,'ePrints_banner_r5_c9');MM_swapImage('ePrints_banner_r5_c9','','/images/eprints/ePrints_banner_r5_c9_f2.gif',1);"><img name="ePrints_banner_r5_c9" src="/images/eprints/ePrints_banner_r5_c9.gif" width="68" height="25" border="0" alt="register" /></a></td>
  488. <td rowspan="2"><a href="/perl/users/home" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133422_4,0,25,null,'ePrints_banner_r5_c10');MM_swapImage('ePrints_banner_r5_c10','','/images/eprints/ePrints_banner_r5_c10_f2.gif',1);"><img name="ePrints_banner_r5_c10" src="/images/eprints/ePrints_banner_r5_c10.gif" width="82" height="25" border="0" alt="user area" /></a></td>
  489. <td rowspan="2"><a href="/help/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133514_5,0,25,null,'ePrints_banner_r5_c11');MM_swapImage('ePrints_banner_r5_c11','','/images/eprints/ePrints_banner_r5_c11_f2.gif',1);"><img name="ePrints_banner_r5_c11" src="/images/eprints/ePrints_banner_r5_c11.gif" width="69" height="25" border="0" alt="Help" /></a></td>
  490. <td rowspan="3" colspan="4"><img name="ePrints_banner_r5_c12" src="/images/eprints/ePrints_banner_r5_c12.gif" width="98" height="40" border="0" alt="" /></td>
  491. <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  492. </tr>
  493. <tr>
  494. <td rowspan="2"><img name="ePrints_banner_r6_c3" src="/images/eprints/ePrints_banner_r6_c3.gif" width="44" height="39" border="0" alt="ePrints home" /></td>
  495. <td><a href="/" onMouseOut="MM_swapImgRestore()" onMouseOver="MM_swapImage('ePrints_banner_r6_c4','','/images/eprints/ePrints_banner_r6_c4_f2.gif',1);"><img name="ePrints_banner_r6_c4" src="/images/eprints/ePrints_banner_r6_c4.gif" width="105" height="24" border="0" alt="ePrints home" /></a></td>
  496. <td><img src="/images/eprints/spacer.gif" width="1" height="24" border="0" alt="" /></td>
  497. </tr>
  498. <tr>
  499. <td><img name="ePrints_banner_r7_c2" src="/images/eprints/ePrints_banner_r7_c2.gif" width="104" height="15" border="0" alt="" /></td>
  500. <td colspan="8"><img name="ePrints_banner_r7_c4" src="/images/eprints/ePrints_banner_r7_c4.gif" width="517" height="15" border="0" alt="" /></td>
  501. <td><img src="/images/eprints/spacer.gif" width="1" height="15" border="0" alt="" /></td>
  502. </tr>
  503. </table></td>
  504. </tr>
  505. <tr><td><table width="100%" style="font-size: 90%; border: solid 1px #ccc; padding: 3px"><tr>
  506. <td align="left"><a href="http://eprints.utas.edu.au/cgi/users/home">Login</a> | <a href="http://eprints.utas.edu.au/cgi/register">Create Account</a></td>
  507. <td align="right" style="white-space: nowrap">
  508. <form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/search" style="display:inline">
  509. <input class="ep_tm_searchbarbox" size="20" type="text" name="q" />
  510. <input class="ep_tm_searchbarbutton" value="Search" type="submit" name="_action_search" />
  511. <input type="hidden" name="_order" value="bytitle" />
  512. <input type="hidden" name="basic_srchtype" value="ALL" />
  513. <input type="hidden" name="_satisfyall" value="ALL" />
  514. </form>
  515. </td>
  516. </tr></table></td></tr>
  517. <tr>
  518. <td class="toplinks"><!-- InstanceBeginEditable name="content" -->
  519.  
  520.  
  521. <div align="center">
  522. <table width="720" class="ep_tm_main"><tr><td align="left">
  523. <h1 class="ep_tm_pagetitle">Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group</h1>
  524. <p style="margin-bottom: 1em" class="not_ep_block"><span class="person_name">Adams, M.J.</span> and <span class="person_name">Ward, C.</span> and <span class="person_name">Thom, J.</span> and <span class="person_name">Bianchi, A.</span> and <span class="person_name">Perrin, E.</span> and <span class="person_name">Coghlan, D.</span> and <span class="person_name">Smith, M.</span> (2007) <xhtml:em>Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group.</xhtml:em> Seminars in Thrombosis and Hemostasis, 33 (3). pp. 226-234. ISSN 0094-6176</p><p style="margin-bottom: 1em" class="not_ep_block"></p><table style="margin-bottom: 1em" class="not_ep_block"><tr><td valign="top" style="text-align:center"><a href="http://eprints.utas.edu.au/1773/1/Adams_etal_2007_(ASTH).pdf"><img alt="[img]" src="http://eprints.utas.edu.au/style/images/fileicons/application_pdf.png" class="ep_doc_icon" border="0" /></a></td><td valign="top"><a href="http://eprints.utas.edu.au/1773/1/Adams_etal_2007_(ASTH).pdf"><span class="ep_document_citation">PDF</span></a> - Full text restricted - Requires a PDF viewer<br />104Kb</td><td><form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/request_doc"><input accept-charset="utf-8" value="2253" name="docid" type="hidden" /><div class=""><input value="Request a copy" name="_action_null" class="ep_form_action_button" onclick="return EPJS_button_pushed( '_action_null' )" type="submit" /> </div></form></td></tr></table><p style="margin-bottom: 1em" class="not_ep_block">Official URL: <a href="http://dx.doi.org/10.1055/s-2007-971808">http://dx.doi.org/10.1055/s-2007-971808</a></p><div class="not_ep_block"><h2>Abstract</h2><p style="padding-bottom: 16px; text-align: left; margin: 1em auto 0em auto">Technology in hemostasis laboratories has evolved enormously during the last&#13;
  525. 30 years. Although many scientists and clinicians will remember the traditional tilt-tube&#13;
  526. techniques to screen for coagulation abnormalities and to monitor anticoagulant therapy,&#13;
  527. the hemostasis laboratory today uses a variety of modern technologies. These include flow&#13;
  528. cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), immunologic&#13;
  529. assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific&#13;
  530. coagulation proteins, and platelet function analyzers. Although these advances in technology&#13;
  531. have resulted in greater capability, productivity, sensitivity, specificity, and ultimately,&#13;
  532. improvement in the clinical care of patients, controversies and limitations remain.&#13;
  533. This article highlights new and emerging technologies in hemostasis and discusses whether&#13;
  534. they have improved or are likely to improve laboratory diagnostics by specifically addressing&#13;
  535. the following: (1) Can new technologies help predict likelihood of thrombosis recurrence?&#13;
  536. (2) Has an understanding of the role of a disintegrin-like and metalloprotease with&#13;
  537. thrombospondin type 1 motifs (ADAMTS13) in microangiopathy resulted in improved&#13;
  538. diagnostic methods for this disorder? (3) Does thrombelastography allow better definition&#13;
  539. of bleeding risk than conventional hemostasis assays, especially in settings of acute&#13;
  540. hemostatic pathology?</p></div><table style="margin-bottom: 1em" cellpadding="3" class="not_ep_block" border="0"><tr><th valign="top" class="ep_row">Item Type:</th><td valign="top" class="ep_row">Article</td></tr><tr><th valign="top" class="ep_row">Additional Information:</th><td valign="top" class="ep_row">Copyright 2007, Georg Thieme Verlag. Definitive version is available online at http://www.thieme-connect.de/ejournals/toc/sth/6268</td></tr><tr><th valign="top" class="ep_row">Keywords:</th><td valign="top" class="ep_row">Hemostasis, laboratory testing, thrombin generation, thrombophilia, bleeding</td></tr><tr><th valign="top" class="ep_row">Subjects:</th><td valign="top" class="ep_row"><a href="http://eprints.utas.edu.au/view/subjects/321008.html">320000 Medical and Health Sciences &gt; 321000 Clinical Sciences &gt; 321008 Haematology</a></td></tr><tr><th valign="top" class="ep_row">ID Code:</th><td valign="top" class="ep_row">1773</td></tr><tr><th valign="top" class="ep_row">Deposited By:</th><td valign="top" class="ep_row"><span class="ep_name_citation"><span class="person_name">Dr Murray J Adams</span></span></td></tr><tr><th valign="top" class="ep_row">Deposited On:</th><td valign="top" class="ep_row">12 Sep 2007</td></tr><tr><th valign="top" class="ep_row">Last Modified:</th><td valign="top" class="ep_row">09 Jan 2008 02:30</td></tr><tr><th valign="top" class="ep_row">ePrint Statistics:</th><td valign="top" class="ep_row"><a target="ePrintStats" href="/es/index.php?action=show_detail_eprint;id=1773;">View statistics for this ePrint</a></td></tr></table><p align="right">Repository Staff Only: <a href="http://eprints.utas.edu.au/cgi/users/home?screen=EPrint::View&amp;eprintid=1773">item control page</a></p>
  541. </td></tr></table>
  542. </div>
  543.  
  544.  
  545.  
  546. <!-- InstanceEndEditable --></td>
  547. </tr>
  548. <tr>
  549. <td><!-- #BeginLibraryItem "/Library/footer_eprints.lbi" -->
  550. <table width="795" border="0" align="left" cellpadding="0" class="footer">
  551. <tr valign="top">
  552. <td colspan="2"><div align="center"><a href="http://www.utas.edu.au">UTAS home</a> | <a href="http://www.utas.edu.au/library/">Library home</a> | <a href="/">ePrints home</a> | <a href="/contact.html">contact</a> | <a href="/information.html">about</a> | <a href="/view/">browse</a> | <a href="/perl/search/simple">search</a> | <a href="/perl/register">register</a> | <a href="/perl/users/home">user area</a> | <a href="/help/">help</a></div><br /></td>
  553. </tr>
  554. <tr><td colspan="2"><p><img src="/images/eprints/footerline.gif" width="100%" height="4" /></p></td></tr>
  555. <tr valign="top">
  556. <td width="68%" class="footer">Authorised by the University Librarian<br />
  557. © University of Tasmania ABN 30 764 374 782<br />
  558. <a href="http://www.utas.edu.au/cricos/">CRICOS Provider Code 00586B</a> | <a href="http://www.utas.edu.au/copyright/copyright_disclaimers.html">Copyright &amp; Disclaimers</a> | <a href="http://www.utas.edu.au/accessibility/index.html">Accessibility</a> | <a href="http://eprints.utas.edu.au/feedback/">Site Feedback</a>  </td>
  559. <td width="32%"><div align="right">
  560. <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><img src="http://www.utas.edu.au/shared/logos/unioftasstrip.gif" alt="University of Tasmania Home Page" width="260" height="16" border="0" align="right" /></a></p>
  561. <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><br />
  562. </a></p>
  563. </div></td>
  564. </tr>
  565. <tr valign="top">
  566. <td><p>  </p></td>
  567. <td><div align="right"><span class="NoPrint"><a href="http://www.eprints.org/software/"><img src="/images/eprintslogo.gif" alt="ePrints logo" width="77" height="29" border="0" align="bottom" /></a></span></div></td>
  568. </tr>
  569. </table>
  570. <!-- #EndLibraryItem -->
  571. <div align="center"></div></td>
  572. </tr>
  573. </table>
  574.  
  575. </body>
  576. </html>